Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Nextgen Bio UK Limited - Exhibit 10.4

EXHIBIT 10.4

INCENTIVE AGREEMENT: 31ST JANUARY 2008

PARTIES

	(1) 	
      NEXTGEN BIOSCIENCE INC., a company incorporated
      under the laws of Nevada, USA, whose UK representative office is at
      4th Floor, 36 Spital Square, London, E1 6DY, England (“the
      Company”).

	 	 
	(2) 	
      DR KAREN ELIZABETH JERVIS of 1 Bellfield Crescent,
      Eddleston, Peebles, EH45 8RQ (“the
Executive”).

WHEREAS

	(A) 	
      The Company and the Executive have entered into an
      Employment Agreement of even date herewith (“Employment Agreement”) under
      which the Executive is retained by the Company to provide services and to
      act as Chief Executive for a period to 31st July 2010 unless
      terminated by either party on three months’ written notice.

	 	 	 
	(B) 	
      The key objectives of the role of the Executive as
      identified by the Company and hereby notified to the Executive are to
      focus on the following areas;

	 	 	 
		
      	

	
      To keep expenses under control.

	 	 	 
		
      	

	
      To run the day to day business of the Company.

	 	 	 
		
      	

	
      To raise new money.

	 	 	 
		
      	

	
      To seek and obtain grants.

	 	 	 
		
      	

	
      To seek and provide exit strategies for the Company’s
      drug targets.

	 	 	 
	(C) 	
      The parties have agreed to enter into this Agreement to
      record the incentives to be offered to the Executive by the Company as a
      reward for achieving the objectives specified in (B)
  above.

IT IS AGREED as follows:

	1. 	
      MONEYRAISING

	 	 	 
		1.1 	
      The Company shall issue to the Executive 1,000,000 of its
      shares of NextGen Bioscience Inc free of charge for every complete
      $10,000,000 in cash raised in the Company during the term of this
      agreement, up to a maximum of 3,000,000 shares (i.e. 1,000,000 shares to
      be issued on $10,000,000 being reached, a further 1,000,000 shares to be
      issued on

1

		
       
	$20,000,000 being reached, and a further
      1,000,000 shares to be issued on $30,000,000 being reached).
	 	 	
       
	
       

	2. 	
      GRANTS

	 	 	
       
	
       

		2.1 	
      The Company shall issue to the Executive 500,000 of its
      shares in NextGen Bioscience Inc free of charge for every complete
      $1,000,000 in cash received by the Company in the form of a grant from a
      third party during the term of this agreement, up to a maximum of
      1,500,000 shares (i.e. 500,000 shares to be issued on $1,000,000 being
      reached, a further 500,000 shares to be issued on $2,000,000 being
      reached, and a further 500,000 shares to be issued on $3,000,000 being
      reached).

	 	 	
       
	
       

	3. 	
      EXIT OF TARGETS

	 	 	
       
	
       

		3.1 	
      The Company shall issue to the Executive 1,500,000 of its
      shares free of charge for every successful exit (“Exit”) from the receipt
      of sale proceeds or receipt of stage payments, royalties or other payments
      in respect of each such exit (“Cash Compensation”) from third parties, in
      the following stages;

	 	 	
       
	
       

			
      3.1.1 
	
      500,000 shares to be issued on $1,000,000 of Cash
      Compensation for a particular Exit being reached;

	 	 	
       
	
       

			
      3.1.2 
	
      a further 500,000 shares to be issued on $6,000,000 of
      Cash Compensation for a particular Exit being reached; and

	 	 	
       
	
       

			
      3.1.3 
	
      a further 500,000 shares to be issued on $15,000,000 of
      Cash Compensation for a particular Exit being reached.

	 	 	
       
	
       

		3.2 	
      The shares issues in 3.1 above shall apply to a maximum
      of five Exits of targets by the Company.

	 	 	
       
	
       

	4. 	
      DURATION

	 	 	
       
	
       

		4.1 	
      This Agreement shall, subject to automatic termination in
      the event of a termination of the Employment Agreement in accordance with
      the terms of this Agreement, commence on 1st February 2008 and
      shall continue until 31st July 2010.

	 	 	
       
	
       

	5. 	
      ISSUE OF SHARES

	 	 	
       
	
       

		5.1 	
      The Company shall issue the shares to be awarded to the
      Executive under this Agreement on or about 31st July 2010. In
      the event of an earlier termination of this Agreement through the
      termination of the Employment Agreement the Company shall issue the shares
      earned by the Executive up to that effective date of termination within 21
      days of the effective date of termination.

	 	 	
       
	
       

		5.2 	
      It is agreed that the Executive will execute a form of
      investment agreement confirming the restricted status of the shares to be
      received

2

			
      under U.S. securities laws. Issuance of the shares will
      be conditional upon delivery of the investment agreement. The investment
      agreement will, among other things, confirm the Executive’s representation
      that she acknowledges that the shares are restricted under U.S. securities
      laws, that she is acquiring the shares for investment and not for
      distribution, that the certificates representing the shares will be
      legended and that she is a sophisticated purchaser able to evaluate the
      risks and merits of an investment in the Company's shares.

	 	 	
       
	
       

	6. 	
      NOTICES

	 	 	
       
	
       

		6.1 	
      Any notice to be given under this Agreement to the
      Executive may be

	 	 	
       
	
       

			
      6.1.1 
	
      given to the Executive personally or

	 	 	
       
	
       

			
      6.1.2 
	
      sent to her by pre-paid first class letter or

	 	 	
       
	
       

			
      6.1.3 
	
      sent by facsimile transmission addressed to her at her
      last known place of residence.

	 	 	
       
	
       

		6.2 	
      Any notice to be given to the Company:

	 	 	
       
	
       

			
      6.2.1 
	
      should be addressed to the Chairman; and

	 	 	
       
	
       

			
      6.2.2 
	
      may be served by leaving it at or sending it by pre-paid
      first class letter to its UK representative office for the time
    being.

	 	 	
       
	
       

		6.3 	
      Any notice served by post shall be deemed to have been
      served forty-eight hours after it was posted and proof that the notice was
      properly addressed, pre-paid and posted shall be sufficient evidence of
      service.

	 	 	
       
	
       

	7. 	
      PRIOR AGREEMENTS

	 	 	
       
	
       

		
      This Agreement cancels and is in substitution for all
      previous letters of engagement, agreements and arrangements (whether oral
      or in writing), other than the Employment Agreement and the Consultancy
      Agreement, relating to the subject matter of incentives hereof between the
      Company or any Group Company and the Executive all of which shall be
      deemed to have been terminated by mutual consent.

	 	 	
       
	
       

	8. 	
      RIGHTS OF THIRD PARTIES

	 	 	
       
	
       

		
      This Agreement does not confer rights on the Consultant's
      spouse or dependants or on any third party.

	 	 	
       
	
       

	9. 	
      GOVERNING LAW AND JURISDICTION

	 	 	
       
	
       

		9.1 	
      This Agreement shall be governed by and interpreted in
      accordance with the law of England.

3

	 	9.2 	
      The parties to this Agreement submit to the exclusive
      jurisdiction of the English Courts in relation to any claim, dispute or
      matter arising out of or relating to this Agreement.

	 	 	 
	 	9.3 	
      Any delay by any party in exercising any of its or her
      rights under this Agreement will not constitute a waiver of such
      rights.

IN WITNESS of which the parties have executed this
Agreement on the date set out above.

EXECUTED by the Company which was delivered when dated,
acting by:

Chief Operating Officer

	Signature 	: /s/ Graham May 
	 	 
	Name 	: Graham May 

EXECUTED by the Consultant which was delivered when
dated:

	Signature 	: /s/ Karen Elizabeth Jervis
  

4ex9-01_formofwaiver.htm

     

     

    EXHIBIT
10.1

    WAIVER

    

    Reference
is made to the Securities Purchase Agreement (the “Agreement”) dated
April 27, 2006, by and among a21, Inc. (“a21”), its wholly
owned subsidiary SuperStock, Inc. (together with a21 and ArtSelect, Inc., the
“Companies”),
the purchasers set forth on Exhibit A to the Agreement (the “Purchasers”) and
Queequeg Partners, L.P. as agent for itself and the Purchasers.  Pursuant
to the terms of the Secured Convertible Term Notes (the “Notes”) issued
pursuant to the Agreement, a quarterly interest payment on the Notes is due on
January 1, 2008, and April 1, 2008 (collectively, the “Interest Payment
Dates”).  Capitalized used herein, but not otherwise defined
shall have the meanings ascribed to them in the Notes.

    

    In order
to assist a21 with implementing its business plan and to improve a21’s
liquidity, the undersigned Purchasers, on behalf of themselves and all of the
other Purchasers, have agreed to waive receipt of any interest payment due to
the Purchasers on the Interest Payment Dates.  As consideration for
the foregoing waiver, the Companies shall issue to each Purchaser a Secured
Convertible Term Note on or about and dated as of April 1, 2008, evidencing the
unpaid interest otherwise due and payable to such Purchaser on the Interest
Payment Dates in substantially the form and upon substantially the same terms
and conditions as the Notes (each an “Interest
Note”).  As further consideration for such waiver, the right of
payment under each Interest Note shall be senior to the right of payment under
the Notes.

    

    Purchasers
representing a majority of the Notes outstanding are required to waive any Event
of Default under the Agreement.  The undersigned Purchasers hereby
waive any Event of Default which has occurred or may occur under the Notes in
connection with or otherwise related to the January 1, 2008, and/or the April 1,
2008, interest payments.

     

    This
Waiver may be executed in any number of counterparts, each of which when so
executed and delivered shall be considered to be an original and all of which
taken together shall constitute one and the same instrument.  Delivery
by telecopier of an executed counterpart of a signature page to this Waiver
shall be effective as delivery of an original executed counterpart of this
Waiver.

    

    Dated as
of January 31, 2008

    

     

    PURCHASER(S):

    
      	
               

               

              By:

            	 
      
	
              Name:

            	
              <Noteholder>

            
	
              Title:

            	
              <Title>

            

    

    

    [Additional
Signatures Follow]

    
      
         

      

      
         

        
          

          1

      

      
         

      

    

    

     

    COMPANIES:

     

    a21,
INC.

    
      	
               

               

              By:

            	 
      
	
              Name:

            	
              Thomas
      Costanza

            
	
              Title:

            	
              Chief
      Financial Officer

            

    

     

    SUPERSTOCK,
INC.

    
      	
               

               

              By:

            	 
      
	
              Name:

            	
              Thomas
      Costanza

            
	
              Title:

            	
              Chief
      Financial Officer

            

    

     

    ARTSELECT,
INC.

    
      	
               

               

              By:

            	 
      
	
              Name:

            	
              Thomas
      Costanza

            
	
              Title:

            	
              Chief
      Financial Officer

            

    

     

    

    

     

      

      2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]